TRACON Pharmaceuticals, Inc. stock is down -21.48% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 February’s closed higher than January.
TRACON Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody. TRC102, a small molecule that is in Phase II clinical trial for the. treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and gliob
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!